Clinical trial Recruiting at 2 sites Phase 3 Interventional Ages 10 to 21

Comparing pooled human plasma and crystalloid for children undergoing spinal fusion for scoliosis

Official title: Pooled Human Plasma vs Crystalloid in The Management of Children Undergoing Instrumented Spinal Fusion for Scoliosis: A Double-Blind, Randomized Clinical Trial

Run by Turku University Hospital · NCT06934278 · Data updated 2026-11-12

This study is testing whether using pooled human plasma instead of a standard fluid can help reduce blood loss during spinal surgery for scoliosis in teenagers.

Quick facts

PhasePhase 3
Study typeInterventional
Ages10 Years to 21 Years
SexAll
Enrollment194 (estimated)
SponsorTurku University Hospital
Government
Locations2 sites (Helsinki and 1 other locations)
StatusRecruiting
StartedMay 2, 2025
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedMay 7, 2025
Trial IDNCT06934278 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adolescents aged 10 to 21 years with idiopathic or neuromuscular scoliosis requiring posterior spinal surgery.

Probably not a fit

Patients with conditions such as immunoglobulin A deficiency, severe obesity, or those requiring more complex surgical interventions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The OCTAGON trial is a Phase 3, randomized, double-blinded, parallel-group clinical trial that aims to evaluate the effectiveness of pooled human plasma versus crystalloid in reducing intraoperative blood loss in adolescents undergoing spinal fusion surgery for scoliosis. A total of 194 participants aged 10 to 21 years with significant scoliosis curves will be enrolled and monitored for outcomes such as blood loss, need for blood transfusions, and postoperative recovery metrics over a minimum follow-up period of two years. The study will also assess the safety of pooled human plasma by recording any adverse events during the trial.

Why it matters

Potential benefit: If successful, this study could significantly reduce the need for blood transfusions and improve surgical outcomes for children undergoing spinal fusion for scoliosis.

How similar studies have gone: While the use of pooled human plasma in pediatric surgery is less explored, similar studies in adult populations have shown promising results in reducing blood loss during major surgeries.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Written informed consent.
* Aged between 10 and 21 years of age
* Scoliosis requiring posterior scoliosis surgery using all pedicle screw technique for AIS (\>45-degree major curve) or NMS (\>50-degree major curve)
* Normal whole spine MRI except for the spinal deformity (only for patients with adolescent idiopathic scoliosis as patients with neuromuscular scoliosis do not typically undergo MR images as they would need general anaesthesia)

Exclusion Criteria:

* Immunoglobulin A-deficiency
* Need for anteroposterior surgery
* Need for three column vertebral resection
* Smoking
* Diabetes mellitus
* Abnormalities in blood coagulation (thromboplastin time below above or below of normal values, 70-130%)
* Blood trombosytes less than 150 x E9/l
* Body mass index over 40
* Allergy or hypersensitivity to study medications or their ingredients
* Pregnancy or breast-feeding, aim of becoming pregnant during the study.
* Participation in another study and receipt of any other investigational agent during 2 year period of current investigation
* Inability to provide written informed consent
* Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.
* A history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.
* Known history of, or documented positive hepatitis B or C or HIV infection Prior or concurrent malignancy
* Aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 x upper-limit of normal
* Creatinine clearance (CrCl) \< 60 ml/min measured by 24-hour urine collection or estimated from the Cockcroft and Gault formula
* Clinically significant ECG findings as judged by the investigator
* Amiodarone medication
* Hyperkalemia
* Renal insufficiency
* AV-block
* Metabolic or respiratory alkalosis
* Hypochlorhydria
* Hypersensitivity for active component or additives.

Where it's running

  • Helsinki University Hospital
    Helsinki, Finland
    Recruiting
  • Turku University Hospital
    Turku, Finland
    Recruiting

Study contacts

  • Principal investigator: Matti Ahonen, MD, Ass Prof, Ortho surgeon — Helsinki University Central Hospital
  • Study coordinator: Ilkka Helenius, MD, orthopaedic surgeon
  • Email: ilkka.helenius@helsinki.fi
  • Phone: +358443380034

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.